.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP01_Ribavirin.Ribavirin .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP01_Ribavirin.Ribavirin| name: | Ribavirin |
| ATC code: | J05AP01 | route: | oral |
| n-compartments | 2 |
Ribavirin is a synthetic nucleoside analog with broad-spectrum antiviral activity. It is primarily used for the treatment of hepatitis C in combination with other drugs and for severe respiratory syncytial virus (RSV) infections in certain populations. Ribavirin is approved for use in combination therapy for hepatitis C virus (HCV) infection and is also used off-label for other viral infections.
Pharmacokinetic parameters reported in healthy adult males after single oral dose.
Jin, R, et al., & Dowling, TC (2012). Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. The AAPS journal 14(3) 571–580. DOI:10.1208/s12248-012-9368-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/22639111
Mensing, S, et al., & Dutta, S (2016). Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. The AAPS journal 18(1) 270–280. DOI:10.1208/s12248-015-9846-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26597291
Suleiman, AA, et al., & Oberoi, RK (2020). Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials. Journal of clinical pharmacology 60(3) 331–339. DOI:10.1002/jcph.1524 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31515816